NVSEF
Novartis AG OTC$144.00
Mkt Cap $274.8B
52w Low $105.15
58.7% of range
52w High $171.29
50d MA $154.17
200d MA $136.71
P/E (TTM)
19.3x
EV/EBITDA
12.2x
P/B
6.1x
Debt/Equity
0.8x
ROE
32.8%
P/FCF
14.5x
RSI (14)
—
ATR (14)
—
Beta
0.52
50d MA
$154.17
200d MA
$136.71
Avg Volume
81.7K
About
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metaboli…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | 2.10 | 1.99 | -5.2% | 145.00 | +0.0% | +0.0% | +0.4% | +1.2% | -0.7% | — | — |
| Feb 4, 2026 | TNS | 1.99 | 2.03 | +2.0% | 152.77 | +0.0% | +0.0% | +0.0% | +4.2% | +4.2% | +3.8% | — |
| Jul 17, 2025 | TNS | 2.35 | 2.06 | -12.3% | 118.66 | +0.0% | +0.0% | +0.0% | -3.5% | -3.5% | -2.9% | — |
| Apr 29, 2025 | TNS | 2.11 | 1.85 | -12.3% | 114.59 | +0.0% | +0.0% | +0.0% | -0.2% | -3.1% | -3.1% | — |
| Jan 31, 2025 | TNS | 1.80 | 1.41 | -21.7% | 101.26 | -0.0% | +3.4% | +3.4% | +4.9% | +4.9% | +3.0% | — |
| Oct 29, 2024 | TNS | 1.94 | 1.57 | -19.1% | 109.60 | +3.3% | -0.3% | -0.3% | -3.1% | -3.1% | -3.1% | — |
| Jul 18, 2024 | TNS | 1.85 | 1.59 | -14.1% | 110.00 | -6.4% | -6.4% | -6.2% | -6.2% | -6.2% | -4.5% | — |
| Apr 23, 2024 | TNS | 1.68 | 1.31 | -22.0% | 96.00 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +1.0% | — |
| Mar 5, 2024 | TNS | 1.65 | 4.11 | +149.1% | 102.00 | +0.0% | +0.0% | +0.0% | +0.0% | -3.2% | -3.6% | — |
| Sep 30, 2023 | TNS | 1.67 | 0.85 | -49.2% | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | — | — | — | — | — | — | — | — |
| May 8 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | — | — | — | — | — | — | — | — |
| Dec 5 | Exane BNP Paribas | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Bryan Garnier | Downgrade | Buy → Neutral | — | $74.67 | $78.90 | +5.7% | +5.7% | +0.2% | +6.8% | +1.3% | +8.8% |
| Sep 19 | Deutsche Bank | Downgrade | Hold → Sell | — | — | — | — | — | — | — | — | — |
| Mar 9 | Argus | Downgrade | Buy → Hold | — | $80.72 | $84.03 | +4.1% | +4.5% | +4.1% | -1.4% | +1.7% | +4.0% |
| Jan 31 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Aug 31 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $85.70 | $87.11 | +1.6% | +1.6% | +0.5% | -4.8% | -4.8% | -0.5% |
| Feb 24 | Guggenheim | Downgrade | Buy → Neutral | — | $94.99 | $93.55 | -1.5% | -5.0% | -6.7% | -8.0% | -8.2% | -13.1% |
| Apr 24 | Guggenheim | Upgrade | Neutral → Buy | — | $76.30 | $78.49 | +2.9% | +2.8% | +3.0% | +7.5% | +1.9% | +6.9% |
Recent Filings
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Novartis's acquisition of Atrium Therapeutics closed at $72.00 per share, providing value to optionholders whose stock options exceeded the exercise price.
Feb 27
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Atrium Therapeutics completed a spin-off from its parent company, creating an independent entity focused on its therapeutic pipeline with separate ownership structure and operational autonomy.
Feb 26
8-K · 7.01
! Medium
Atrium Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Avidity Biosciences plans to distribute all Atrium Therapeutics shares pro rata to its stockholders, creating a spinoff that will give Avidity investors direct ownership in the independent company.
Feb 26
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Novartis's acquisition of Atrium Therapeutics (RNA) through Avidity Biosciences is progressing toward shareholder vote, with the definitive proxy statement filed January 30, 2026.
Feb 23
8-K · 5.02
!!! Very High
Tarsus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Tarsus Pharmaceuticals appointed David E.I. Pyott as a Class III director, adding experienced leadership to its board governance.
Feb 18
8-K · 5.02
!!! Very High
Entera Bio Ltd. -- 8-K 5.02: Executive Change
Entera Bio Ltd. appointed Geno J. Germano as Class III director effective February 4, 2026, strengthening board governance and potentially signaling strategic direction changes.
Feb 9
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
This filing appears to contain standard forward-looking statement disclaimers rather than material news, providing limited actionable information for investors regarding Atrium Therapeutics' operations or financial condition.
Feb 3
Data updated apr 27, 2026 7:39pm
· Source: massive.com